It’s a Wrap! Key trends observed in Clinical Trials for 2022
The clinical trial landscape has evolved significantly over the past few years, driven by advances in technology, increasing patient diversity, and changing regulations. As we look back on the clinical trials of 2022, several key trends have emerged that are reshaping the industry and driving new innovations. In this blog, we'll explore some of these trends, supported by real-life data, and discuss their implications for the future of clinical trials.
Consequences of a More Geographically Diverse Participant Pool:
Clinical trials have traditionally been conducted in a limited number of geographic locations, often in developed countries. However, advances in technology have made it possible to conduct trials in more remote and diverse locations, providing access to a broader range of patients. In 2022, this trend continued, with a growing number of trials being conducted in emerging markets, such as India and China. This shift has led to a more representative sample of patients, improving the generalizability of trial results and making it possible to develop treatments that are better suited to diverse populations.
A recent report by The National Institute for Health Research (NIHR) has found that 86% of Randomised Clinical Trails (RCTs) participants were white. Black participants comprised 4% and a further 5% of participants were Asian. The report suggests a more geographically diverse participant pool can improve the generalizability of trial results and help to develop treatments that are better suited to diverse populations.
Increasing the Personalization of the Patient Experience:
Personalized medicine is one of the most exciting trends in clinical trials, and it has become increasingly important as patients become more involved in their own healthcare. In 2022, we saw a growing number of trials that were designed to be more patient-centric, with a focus on optimizing the patient experience. For example, remote monitoring and telemedicine technologies have made it possible for patients to participate in trials from the comfort of their own homes, reducing the burden of travel and making it easier for them to participate. Additionally, trial designs have become more flexible, allowing for individualized dosing and treatment regimens, improving the chances of success for patients.
A study conducted by the Mayo Clinic in the US found that a personalized approach to clinical trials, such as offering patient-centred support services, can improve patient engagement and adherence to treatment, leading to better outcomes.
Improved Trial Data Collection Options for Richer, More Precise Trial Data:
One of the most important trends in clinical trials over the past few years has been the use of electronic data collection methods, such as electronic patient-reported outcomes (ePRO) and electronic clinical outcome assessments (eCOA). In 2022, these technologies continued to evolve, providing more accurate, real-time data that is easier to analyse and interpret. This has led to more precise trial results, helping to support faster and more informed decision-making in the development of new treatments.
More Attention Should Be Paid to Patient Privacy, Especially in Place of Expanding Digital Storage and Sharing:
With the increasing use of digital technologies in clinical trials, privacy concerns have become increasingly important. In 2022, we saw a growing awareness of the need to protect patient privacy, especially in light of expanding digital storage and sharing. This has led to the development of new privacy-enhancing technologies, such as blockchain and secure data sharing platforms, to ensure that patient data is protected and used appropriately.
Regaining Trust After Adverse Effects of the Epidemic and Debates
The COVID-19 pandemic has had a profound impact on the world, including the clinical trial industry. In the wake of the pandemic, there have been debates about the role of public health in clinical trials, leading to a loss of trust in the industry. A study conducted by the London School of Hygiene and Tropical Medicine in the UK found that the COVID-19 pandemic has had a significant impact on public trust in clinical trials, with many people concerned about the safety of participating in trials during the pandemic. In 2022, we saw a growing focus on regaining that trust, with an emphasis on transparency, ethics, and responsible conduct. This has involved developing new guidelines and protocols to ensure that clinical trials are conducted in a safe and ethical manner, and that the interests of patients are protected.
The year 2022 saw several significant trends in clinical trials, including increased geographical diversity of participants, a focus on personalizing the patient experience, improved data collection methods, increased attention to patient privacy, and the need to regain trust after the COVID-19 pandemic. As the industry continues to evolve, it will be important to continue to monitor these trends and to adapt to meet the changing needs of patients, healthcare providers, and regulatory authorities.
i-Pharm Consulting is a leading provider of staffing services in the Clinical space. We support our clients throughout the entire drug development lifecycle, from drug discovery to pre-clinical research and clinical trials. Get in touch here to find out more.